← Back to Patent Explorer
US4456550A Expired / Lapsed US ⏱️ 0.0 years remaining

Vascular permeability factor

Assignee: ISRAEL HOSPIRAL ASSOCIATION
•
Filing: 1982-11-22
•
Granted: 1984-06-26
•
Expires: 2002-11-22
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A purified vascular permeability protein factor and method of manufacture, wherein the factor has the following characteristics: (a) in an aqueous solution (0.01 M Na3PO4, pH 7) whose concentration of NaCl is varied linearly, the factor is eluted from a heparin-Sepharose chromatography column in a peak centered at 0.4 M NaCl; (b) in an aqueous solution of Na3PO4 (pH 7.0) whose concentration is varied linearly, the factor is eluted from a hydroxylapatite column in a peak centered at 0.25 M Na3PO4; (c) when subjected to SDS gel electrophoresis in a 7.5% polyacrylamide slab gel (0.375 M tris-HCl (pH 8.8), 0.1% SDS) at 35 milliamps and 4 DEG C., the factor is localized to a region corresponding to a molecular weight between 34,000 and 45,000 daltons.

Inventors

  • 👤 Harold F. Dvorak
  • 👤 Donald R. Senger

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 10:13
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C12; C12N; C12N1/00; C12P; C12P21/00; A; A61; A61K; A61K38/00; C12R; C12R2001/00; C12R2001/91; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/828

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 148 words
A fast-acting purified protein factor which affects vascular permeability within 5 minutes of the time of injection and has little residual effect 20 minutes after injection and has the following characteristics: (a) in an aqueous solution (0.01 M Na 3 PO 4 , pH 7) whose concentration of NaCl is varied linearly, the factor is eluted from a heparin-Sepharose chromatography column in a peak centered at 0.4 M NaCl; (b) in an aqueous solution of Na 3 PO 4 (pH 7.0) whose concentration is varied linearly, the factor is eluted from a hydroxylapatite column in a peak centered at 0.25 M Na 3 PO 4 ; (c) when subjected to SDS gel electrophoresis in a 7.5% polyacrylamide slab gel (0.375 M tris-HCl (pH 8.8), 0.1% SDS) at 35 milliamps, 4° C., the factor is localized to a region corresponding to a molecular weight between 34,000 and 45,000 daltons.
Claim 2
Dependent Claim 148 words
A fast-acting purified protein factor which affects vascular permeability within 5 minutes of the time of injection and has little residual effect 20 minutes after injection and has the following characteristics: (a) in an aqueous solution (0.01 M Na 3 PO 4 , pH 7) whose concentration of NaCl is varied linearly, the factor is eluted from a heparin-Sepharose chromatography column in a peak centered at 0.4 M NaCl; (b) in an aqueous solution of Na 3 PO 4 (pH 7.0) whose concentration is varied linearly, the factor is eluted from a hydroxylapatite column in a peak centered at 0.25 M Na 3 PO 4 ; (c) when subjected to SDS gel electrophoresis in a 7.5% polyacrylamide slab gel (0.375 M tris-HCl (pH 8.8), 0.1% SDS) at 35 milliamps, 4° C., the factor is localized to a region corresponding to a molecular weight between 34,000 and 45,000 daltons.
Claim 3
Dependent Claim 26 words
The factor of claim 1 further characterized in that one mole of said factor increases vascular permeability by an amount equivalent to 800 moles of histamine.
Claim 4
Dependent Claim 37 words
The factor of claim 1 wherein the vascular permeability activity of said factor is unaffected by the presence of an inhibitor selected from the group consisting of soybean trypsin inhibitor, pepstatin A, promethazine, mepyramine, cimetidine, and indomethacin.
Claim 5
Dependent Claim 30 words
The factor of claim 1 wherein said factor is derived from fluids that are biologically generated by mammalian tumor cells selected from the group consisting of sarcoma and carcinoma cells.
Claim 6
Dependent Claim 59 words
The factor of claim 4 wherein said tumor cells are selected from the group consisting of line 10 and line 1 bile duct carcinoma guinea pig cells, TA3-St mouse carcinoma cells, HSV-NIL8 hamster sarcoma cells, B77 Rat 1 and RR 1022 rat sarcoma cells, 104 Cl fibrosarcoma guinea pig cells, MOPC 21 myeloma cells, and Balb/c 3T3 sarcoma cells.
Claim 7
Dependent Claim 17 words
A therapeutic agent comprising a protein factor according to claim 1 and a non-toxic therapeutically acceptable carrier.
Claim 8
Dependent Claim 13 words
A purified antibody generated in response to a factor according to claim 1.
Claim 9
Dependent Claim 16 words
A therapeutic agent comprising an antibody according to claim 7 and a non-toxic therapeutically acceptable carrier.
Claim 10
Independent Claim 84 words
A method of making a fast-acting purified protein factor for controlling vascular permeability comprising the following steps: (a) incubating tumor cells in an environmental medium, said tumor cells being selected from the group comprising sarcoma and carcinoma tumor cells; (b) separating said cells from said medium; (c) purifying said factor from said medium; wherein said purification step comprises subjecting a fluid containing said protein to SDS gel electrophoresis and collecting said protein from a region corresponding to a molecular weight between 34,000 and 45,000.
Claim 11
Independent Claim 84 words
A method of making a fast-acting purified protein factor for controlling vascular permeability comprising the following steps: (a) incubating tumor cells in an environmental medium, said tumor cells being selected from the group comprising sarcoma and carcinoma tumor cells; (b) separating said cells from said medium; (c) purifying said factor from said medium; wherein said purification step comprises subjecting a fluid containing said protein to SDS gel electrophoresis and collecting said protein from a region corresponding to a molecular weight between 34,000 and 45,000.

References Cited (Backward Citations)

US4335107A Cited
US4348376A Cited
US4342748A Cited
US4359457A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-06-26 1987-12-26 1988-06-26 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-06-26 1991-12-26 1992-06-26 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-06-26 1995-12-26 1996-06-26 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag